Kidney cancer clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 10, 2006, Pages 1072-1081

  Motzer, Robert J ^a   Bolger, Graeme B ^a   Boston, Barry ^a   Carducci, Michael A ^a   Fishman, Mayer ^a   Hancock, Steven L ^a   Hauke, Ralph J ^a   Hudes, Gary R ^a   Jonasch, Eric ^a   Kantoff, Philip ^a   Kuzel, Timothy M ^a   Lange, Paul H ^a   Levine, Ellis G ^a   Logothetis, Chris ^a   Margolin, Kim A ^a   Pohar, Kamal ^a   Redman, Bruce G ^a   Robertson, Cary N ^a   Samlowski, Wolfram E ^a   Sheinfeld, Joel ^a  

^a NONE

Author keywords

Clear cell tumors; Kidney disease; NCCN Clinical Practice Guidelines; Nephrectomy; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; HUMAN; INCIDENCE; KIDNEY CARCINOMA; MEDULLARY CARCINOMA; NEEDLE BIOPSY; NEPHRECTOMY; PROGNOSIS; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; VON HIPPEL LINDAU DISEASE;

EID: 33751558602     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0089     Document Type: Conference Paper

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002;11:37-42.
3. DeVita VT Jr, Hellman S, Rosenberg SA, et al. Cancer Principles and Practice of Oncology, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
4. Choyke PL. Hereditary renal cancers. Radiology 2003;226:33-46.
5. Hollingsworth JM, Miller DC, Dunn RL, et al. Surgical management of low-stage renal cell carcinoma: technology does not supersede biology. Urology 2006;67:1175-1180.
6. Shuch B, Lam JS, Belldegrun AS. Open partial nephrectomy for the treatment or renal cell carcinoma. Curr Urol Rep 2006;7:31-38.
7. Leibovich BC, Blute ML, Cheville JC, et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;171:1066-1070.
8. Rouviere, O, Bouvier R, Negrier S, et al. Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up. Nat Clin Pract Oncol 2006;3:200-213.
9. Messing EM, Manola J, Wilding O, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003;21:1214-1222.
10. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial. J Clin Oncol 2003;21:3133-3140.
11. Trump DL, Elson P, Propert K, et al. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 1996;15:253.
12. Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261-2266.
13. Flanigan RC, Mickisch C, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer. A combined analysis. J Urol 2004;171:1071-1076.
14. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-1659.
15. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-970.
16. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1273-1278.
17. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-3132.
18. Dutcher JP, Fisher RI, Weiss G, et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997;3:157-162.
19. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-141.
20. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2005;23(Suppl 1):380s. Abstract 4510.
21. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
22. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
23. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524.
24. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first line systemic therapy for patients with metastatic renal cell carcinoma [abstract]. J Clin Oncol 2006;24(Suppl 1):2s. Abstract LBA3.
25. Wenzel C, Locker G, Schmidinger M, et al. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney 2002;39:48-54.
26. Oevermann K, Buer L, Hoffmann R, et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 2000;83:583-587.
27. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
28. Stadler WM, Halabi S, Ernstoff MS, et al. A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B #90008 [abstract]. J Clin Oncol 2004;22. Abstract 4515.
29. Hudes G, Carducci M, Tomczak P, et al. A phase 3, randomized, 3 arm study of temsirolimus or interferon-alpha or the combination of TEMSR + IFN in the treatment of first line, poor-risk with advanced renal cell carcinoma. J Clin Oncol 2006;24(Suppl 1):2s. Abstract LBA4.